ElutiaELUT
ELUT
About: Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Employees: 54
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
10% more funds holding
Funds holding: 29 [Q3] → 32 (+3) [Q4]
6% more capital invested
Capital invested by funds: $46.7M [Q3] → $49.3M (+$2.59M) [Q4]
2.61% more ownership
Funds ownership: 40.98% [Q3] → 43.59% (+2.61%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
156%
upside
Avg. target
$8
156%
upside
High target
$8
156%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Ross Osborn 35% 1-year accuracy 16 / 46 met price target | 156%upside $8 | Overweight Reiterated | 7 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ELUT published over the past 30 days
Neutral
Seeking Alpha
5 days ago
Elutia Inc. (ELUT) Q4 2024 Earnings Call Transcript
Elutia Inc. (NASDAQ:ELUT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants David Carey – FINN Partners C. Randal Mills – Chief Executive Officer Matt Ferguson – Chief Financial Officer Conference Call Participants Ross Osborn – Cantor Fitzgerald Frank Takkinen – Lake Street Capital Markets Operator Good afternoon, ladies and gentleman.
Neutral
GlobeNewsWire
5 days ago
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out
– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
2 weeks ago
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025
SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
Neutral
GlobeNewsWire
1 month ago
Elutia Announces $15.0 Million Registered Direct Offering
SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company's Class A common stock at a purchase price of $2.50 per share and 480,000 prefunded warrants to purchase up to 480,000 shares of the Company's Class A common stock at a purchase price of $2.499 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $15.0 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about February 4, 2025, subject to customary closing conditions.
Negative
Zacks Investment Research
2 months ago
Are Medical Stocks Lagging ELUTIA INC (ELUT) This Year?
Here is how Elutia Inc. (ELUT) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Neutral
Seeking Alpha
3 months ago
Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript
Elutia Inc. (NASDAQ:ELUT ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Matt Steinberg – FINN Partners Randy Mills – Chief Executive Officer Matt Ferguson – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Third Quarter 2024 Financial Results Call.
Neutral
GlobeNewsWire
4 months ago
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET).
Neutral
GlobeNewsWire
5 months ago
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices
EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model
Neutral
GlobeNewsWire
6 months ago
Elutia Celebrates First Year
Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible.
Neutral
GlobeNewsWire
6 months ago
Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.
Charts implemented using Lightweight Charts™